Bloom Science
Biotechnology company developing therapeutics targeting the gut-immune-brain axis, with a focus on neurological conditions including epilepsy and other disorders linked to gut-brain communication.
Notes
Bloom Science is a biotechnology company pioneering a new approach to treating neurological diseases by targeting the gut-immune-brain axis. The company is developing therapeutics that modulate the complex interactions between the gut microbiome, immune system, and brain to treat conditions such as epilepsy.
The company's approach is based on growing scientific evidence that the gut microbiome and immune system play significant roles in brain function and neurological health, opening new therapeutic avenues for conditions that have been difficult to treat with traditional approaches.
Team
- Sam Bhavnani - Co-Founder and CEO
- Scientific founders with expertise in microbiome and neuroscience
Additional Research Findings
- Backed by Apollo Health Ventures
- Focus on gut-immune-brain axis therapeutics
- Lead programs in epilepsy
- Novel approach to neurological diseases
- San Francisco-based biotech
- Leveraging microbiome-brain connection research
- Targeting conditions with limited treatment options
Sources
- Bloom Science Official Website
- Bloom Science LinkedIn
- Apollo Health Ventures Portfolio
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Apollo Health Ventures | Dusseldorf, Germany / Boston, USA | biotech-focused | seedseries-a+1 | 15 |